Scrambler Therapy® Technology MC-5A
(International Patent)

FDA 510(k) Clearance: # K142666 for
Delta International Services & Logistics
CE Certified: #CE 0476


The Scrambler Therapy® device is a U.S. FDA 510(k)-cleared and European CE mark-certified pain therapy medical device for the non-invasive treatment of chronic neuropathic and oncologic pain. This medical device has been developed in Italy by Prof. Giuseppe Marineo for the treatment of chronic neuropathic and oncologic pain resistant to opiates and other types of treatment.

Treatment using the Scrambler Therapy  device avoids the harmful, potentially fatal, adverse side effects. The Scrambler Therapy  device has been used to successfully treat thousands  patients worldwide, where it has been shown to be effective in treating neuropathic and oncologic pain. Scrambler Therapy is a stand-alone medical electroanalgesia device, and does not require combinations with other analgesic therapies.

DIS&L through its law firm is the only company authorized to sign international exclusive agreements in all international area, provide maintenance and distributor support for method usage training and other logistics needs. To request a national exclusive agreement the candidate distributor must have minimum requirements listed on the “Distributor Requirement” page.


Scrambler Therapy® if correctly used is a control tool for severe chronic neuropathic and cancer pain.  Scrambler Therapy is very effective, non-invasive and mainly to be used in ambulatory care and hospital facilities. If carried out correctly the analgesic effect during the treatment  is very rapid. In just a couple of seconds the pain perception completely disappears. This is true even in cases where pain is of high intensity and non responsive  or poorly responsive to opioids or other electro-analgesia devices such as TENS or implanted devices.

Clinical efficacy

Short and long term effects of a single treatment cycle depend on the type of pathology and other variables. In most cases of benign pain one treatment cycle is enough to produce pain relief for at least two months, but can even exceed 12 months if neuropathic damage is limited (mono-radicular) or the pathology has no evolution feature. Other variables that influence the treatment outcome are pharmaceutical interactions. Immediate analgesic efficacy during the treatment is a constant factor regardless of pathology and pain intensity.


For more information visit the official "Scrambler Therapy"® scientific and clinical information website



U.S. DIS&L Division